Silent-Plaque PCSK9i Finder
A software tool that searches medical records to find patients who would benefit from a specific cholesterol drug.
An EHR population-health module that mines imaging reports and problem lists to find patients with documented atherosclerosis (or diabetes) and LDL cholesterol ≥90 mg/dL who have never had a heart attack or stroke — the exact group now proven to benefit from PCSK9 inhibitors — and hands clinicians a ranked treatment-candidacy worklist.
Concept
A population-health module (SMART on FHIR plug-in or native EHR build) that continuously scans data health systems already hold and assembles a ranked worklist of patients matching the newly proven PCSK9-inhibitor population: evidence of atherosclerosis (coronary artery calcium >0, plaque or stenosis on coronary CT angiography or carotid ultrasound, ABI <0.9, peripheral artery disease or asymptomatic carotid stenosis on the problem list) or diabetes, a most-recent LDL cholesterol ≥90 mg/dL, and no history of myocardial infarction or stroke. Each worklist row carries the trial's key numbers and a one-click action to route the patient to their primary-care physician or lipid clinic for a PCSK9-inhibitor candidacy conversation. The single wedge: turn an invisible, previously ineligible population into a concrete, prioritized worklist the day the evidence lands.
Why now
VESALIUS-CV [0] randomized 12,257 patients with atherosclerosis or diabetes, no prior MI or stroke, and LDL ≥90 mg/dL to evolocumab 140 mg every 2 weeks or placebo: after a median 4.6 years of follow-up, the 5-year 3-point MACE rate was 6.2% vs 8.0% (HR 0.75, 95% CI 0.65–0.86) and 4-point MACE 13.4% vs 16.2% (HR 0.81, 95% CI 0.73–0.89), both P<0.001, with no between-group difference in safety events — the first demonstration that PCSK9 inhibition prevents first cardiovascular events. Today's PCSK9i identification workflows were built for secondary prevention and familial hypercholesterolemia, so nobody systematically looks for these event-free patients. The asymptomatic carotid stenosis trial [5] reinforces that intensive medical management — not revascularization — is the lever for stable, imaging-identified plaque, and its ≥70% asymptomatic stenosis population is exactly the kind of ultrasound-documented, event-free atherosclerosis this finder surfaces. Every eligibility criterion in [0] (LDL ≥90, diabetes, atherosclerosis evidence, absence of MI/stroke codes) is machine-queryable from existing EHR data.
Written by GLM · 12 Oct 2026
AI assessment
A highly focused, evidence-backed clinical decision support tool that converts a new trial result into a concrete patient pipeline for a high-value drug class.
- Evidence strength 5/5
- The idea maps directly to the specific inclusion/exclusion criteria of the VESALIUS-CV trial, which provides high-quality randomized controlled trial evidence for this exact population.
- Market pull 4/5
- Health systems and pharma (Amgen) have strong incentives to identify eligible patients for high-cost, high-efficacy therapies, though reimbursement hurdles for primary prevention may exist.
- Novelty & moat 3/5
- While the clinical insight is new, the mechanism (EHR mining for eligibility) is a known pattern, similar to the Pack-Years Miner, but applied to a distinct and high-value medical gap.
- Feasibility 5/5
- The required data (LDL labs, ICD-10 codes for diabetes/PAD, and imaging reports) are standard EHR elements, making a SMART on FHIR implementation straightforward.
- Wedge clarity 5/5
- The wedge is exceptionally sharp: a single, prioritized worklist for a specific drug candidacy based on a newly published trial.
- Simplicity / focus 5/5
- The product is a single-purpose utility with one clear function, avoiding the 'platform' trap.
Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Amgencompany
Maker of evolocumab (Repatha) and funder of VESALIUS-CV; every patient the worklist surfaces is a candidate for the therapy its trial just validated in a previously uncovered population.
- Family Heart Foundationorganization
Runs patient-finding initiatives for undertreated high cholesterol; a tool that systematically finds event-free patients with documented plaque and LDL ≥90 extends its core case-finding mission.
- Geisingerorganization
Integrated, value-oriented health system with mature EHR-based population-health infrastructure; preventing first MACE events in its attributed patients avoids downstream costs it directly bears.
- Epic!company
Could ship this as a standard population-health worklist; an evidence-backed, same-day-useful module differentiates its value-based care tooling for health-system customers.
Research it builds on
- Medical Management and Revascularization for Asymptomatic Carotid StenosisThomas G. Brott, George Howard, Brajesh K. Lal et al. · 2025 · 132 citationsAll ideas from this paper →
- Evolocumab in Patients without a Previous Myocardial Infarction or StrokeErin Ann Bohula, Nicholas Marston, Ajay K. Bhatia et al. · 2025 · 112 citationsAll ideas from this paper →